{
    "nctId": "NCT01421472",
    "briefTitle": "A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer",
    "officialTitle": "A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 196,
    "primaryOutcomeMeasure": "Number of Participants With Pathologic Complete Response (pCR) (Rate of pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological confirmation of ER positive, HER2 negative invasive breast cancer (Group 1) or invasive triple-negative breast cancer (Group 2)\n* Free of metastatic disease\n* \u2265 18 years old\n* Female\n* Had no prior treatment for any cancer\n* Eligible for treatment with paclitaxel, doxorubicin and cyclophosphamide\n\nExclusion Criteria:\n\n* Have a history of severe allergic reactions to paclitaxel or other drugs formulated in Cremaphor\u00ae EL\n* Are pregnant or breastfeeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}